Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/111573
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer
Author: Lin, H.
Lee, B.
Castillo, L.
Spielman, C.
Grogan, J.
Yeung, N.
Kench, J.
Stricker, P.
Haynes, A.
Centenera, M.
Butler, L.
Shreeve, S.
Horvath, L.
Daly, R.
Citation: The Prostate, 2018; 78(4):308-317
Publisher: Wiley
Issue Date: 2018
ISSN: 0270-4137
1097-0045
Statement of
Responsibility: 
Hui-Ming Lin, Brian Y. Lee, Lesley Castillo, Calan Spielman, Judith Grogan, Nicole K. Yeung, James G. Kench, Phillip D. Stricker, Anne-Maree Haynes, Margaret M. Centenera, Lisa M. Butler, S. Martin Shreeve, Lisa G. Horvath, Roger J. Daly
Abstract: Background: Docetaxel, the standard chemotherapy for metastatic castration-resistant prostate cancer (CRPC) also enhances the survival of patients with metastatic castration-sensitive prostate cancer (CSPC) when combined with androgen-deprivation therapy. Focal Adhesion Kinase (FAK) activation is a mediator of docetaxel resistance in prostate cancer cells. The aim of this study was to investigate the effect of the second generation FAK inhibitor VS-6063 on docetaxel efficacy in pre-clinical CRPC and CSPC models. Methods: Docetaxel-resistant CRPC cells, mice with PC3 xenografts, and ex vivo cultures of patient-derived primary prostate tumors were treated with VS-6063 and/or docetaxel, or vehicle control. Cell counting, immunoblotting, and immunohistochemistry techniques were used to evaluate the treatment effects. Results: Docetaxel and VS-6063 co-treatment caused a greater decrease in the viability of docetaxel-resistant CRPC cells, and a greater inhibition in PC3 xenograft growth compared to either monotherapy. FAK expression in human primary prostate cancer was positively associated with advanced tumor stage. Patient-derived prostate tumor explants cultured with both docetaxel and VS-6063 displayed a higher percentage of apoptosis in cancer cells, than monotherapy treatment. Conclusions; Our findings suggest that co-administration of the FAK inhibitor, VS-6063, with docetaxel represents a potential therapeutic strategy to overcome docetaxel resistance in prostate cancer.
Keywords: Chemoresistance; defactinib; Docetaxel; focal adhesion kinase; prostate cancer; VS-6063
Rights: © 2018 Wiley Periodicals, Inc.
RMID: 0030080737
DOI: 10.1002/pros.23476
Grant ID: http://purl.org/au-research/grants/nhmrc/535903
http://purl.org/au-research/grants/nhmrc/1058540
http://purl.org/au-research/grants/arc/FT130101004
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.